Tisotumab Vedotin-tftv Drug Asset Due Diligence Report 2026

This Tisotumab Vedotin-tftv Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Tisotumab Vedotin-tftv can convert its Antibody drug conjugate (ADC) profile and Tubulin x tissue factor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tisotumab Vedotin-tftv (query alias: tisotumab vedotin)
Modality / target	Antibody drug conjugate (ADC); Tubulin x tissue factor; Tubulin inhibitors, tissue factor inhibitors
Highest global status	Approved
Originator	Seagen, Inc.
Active developers	Genmab A/S, Rps Medical Technology (Beijing) Co Ltd, Seagen, Inc.

The MCP disease footprint includes Advanced Cervical Carcinoma, Metastatic Cervical Carcinoma, Recurrent Cervical Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06952660	Phase 4	Recruiting	100	Type, incidence and severity of ocular adverse events (AEs)
NCT07672782	Phase 2	Not yet recruiting	28	Overall Response Rate
NCT05866354	Phase 1	Completed	19	PK parameter AUC of tisotumab vedotin

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial

Phase 3; n=101; evaluation: Positive. Reported fields: mPFS = 2.0 month ( 1.5 - 3.0); mPFS = 4.0 month ( 3.0 - 4.4)

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study

Phase 1/2; n=139; evaluation: Positive. Reported fields: ORR = 65.8 % ; ORR = 40.6 % ; ORR = 54.5 %

609MO - Tisotumab vedotin vs investigator’s choice of chemotherapy as second- or third-line (2L/3L) treatment for Chinese patients (pts) with recurrent or metastatic cervical cancer (r/mCC) in innovaTV 301

Phase 3; n=74; evaluation: Positive. Reported fields: ORR = 5.1 % ( 0.6 - 17.3); ORR = 14.3 % ( 4.8 - 30.3)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tisotumab Vedotin-tftv addresses Advanced Cervical Carcinoma, Metastatic Cervical Carcinoma, Recurrent Cervical Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Antibody drug conjugate (ADC)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-09-27	Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)	Approved	US$30.0M upfront; US$30.0M stated total
2011-04-19	Genmab A/S and Seattle Genetics, Inc. Expand Antibody-Drug Conjugate Collaboration	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods of treating cancer with Anti-tissue factor antibody-drug conjugates”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

CLDN18.2 assay, cutoff, and intratumoral heterogeneity
Payload-related toxicity and dose intensity
Crowding from antibodies, bispecifics, CAR-Ts, and competing ADCs

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO